Alpha 2.0
Login Register
» Authors » R Bissonnette

R Bissonnette

Explore the profile of R Bissonnette including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 80
Citations 1511
Followers 0
Related Specialties
Dermatology
Infectious Diseases
General Surgery
Top 10 Co-Authors
C W Lynde
C Maari
H Lui
Y Poulin
C Bolduc
S Nigen
D R Green
D I McLean
D Thaci
G Viau
Published In
J Eur Acad Dermatol Venereol
Br J Dermatol
Proc Natl Acad Sci U S A
Int J Dermatol
J Am Acad Dermatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Adaptive designs in dermatology clinical trials: Current status and future perspectives
Potvin D, DAngelo P, Bennett S, Jankicevic J, Bissonnette R
J Eur Acad Dermatol Venereol . 2024 Apr; 38(9):1694-1703. PMID: 38619384
Current drug development strategies present many challenges that can impede drug approval by regulatory agencies. Alternative study models, such as adaptive trial designs, have recently sparked interest, as they provide...
2.
Harmonizing body surface area assessments between the Eczema Area and Severity Index, SCORing Atopic Dermatitis, and handprint methods utilizing one shared measurement-A proposal to improve efficiency and reduce error in atopic dermatitis trials
Jacobson M, Seshadri R, Bissonnette R, Paller A, Weidinger S, Thyssen J, et al.
J Eur Acad Dermatol Venereol . 2024 Feb; 38(10):e830-e832. PMID: 38385652
No abstract available.
3.
Tapinarof for psoriasis and atopic dermatitis: 15 years of clinical research
Bissonnette R, Saint-Cyr Proulx E, Jack C, Maari C
J Eur Acad Dermatol Venereol . 2023 Jan; 37(6):1168-1174. PMID: 36708084
Tapinarof is a topical, aryl-hydrocarbon receptor agonist that has recently received FDA-approval for the treatment of psoriasis. This novel therapeutic has also been shown to be effective for atopic dermatitis...
4.
Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events
Bissonnette R, Eichenfield L, Simpson E, Thaci D, Kabashima K, Thyssen J, et al.
J Eur Acad Dermatol Venereol . 2023 Jan; 37(5):976-983. PMID: 36652273
Despite the emergence of novel targeted treatments for atopic dermatitis (AD), there is a lack of guidelines on standardizing analysis of clinical trial data. To define and estimate meaningful treatment...
5.
Sensitivity of clinician-assessed efficacy outcome measurement instruments in trials of topical therapies for atopic dermatitis: a systematic review and meta-analysis
Legare S, Chagnon M, Palijan A, Kojok K, Bissonnette R
J Eur Acad Dermatol Venereol . 2021 Oct; 36(2):196-212. PMID: 34661930
The rising prevalence of atopic dermatitis (AD) in developing countries and its substantial socioeconomic impact have furthered research over the last two decades giving way to advances in its aetiopathogenesis...
6.
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials
Bieber T, Thyssen J, Reich K, Simpson E, Katoh N, Torrelo A, et al.
J Eur Acad Dermatol Venereol . 2020 Sep; 35(2):476-485. PMID: 32926462
Background: Janus kinase (JAK) inhibition is a new mode of action in atopic dermatitis (AD); clarity about drug class safety considerations in the context of AD is important. Baricitinib, an...
7.
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
Simpson E, Lacour J, Spelman L, Galimberti R, Eichenfield L, Bissonnette R, et al.
Br J Dermatol . 2020 Jan; 183(2):242-255. PMID: 31995838
Background: Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids. Objectives: To evaluate the...
8.
Incidence of cardiovascular events among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: pooled data from three large randomised clinical trials
Bissonnette R, Fernandez-Penas P, Puig L, Mendelsohn A, Rozzo S, Menter A
J Eur Acad Dermatol Venereol . 2019 Aug; 34(1):e21-e24. PMID: 31403725
No abstract available.
9.
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study
Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J, et al.
Br J Dermatol . 2019 Mar; 181(4):733-742. PMID: 30919407
Background: ASN002 is an oral dual inhibitor of Janus kinase and spleen tyrosine kinase, which are involved in the pathogenesis of atopic dermatitis (AD) through their regulatory role on T...
10.
Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey-based position statement
Leshem Y, Bissonnette R, Paul C, Silverberg J, Irvine A, Paller A, et al.
J Eur Acad Dermatol Venereol . 2019 Mar; 33(5):807-815. PMID: 30859656
Background: As novel systemic therapeutics for patients with atopic dermatitis (AD) are developed, ethical and methodological concerns regarding placebo-controlled-trials (PCT) have surfaced. Objective: To guide the design and implementation of...